Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Accounts Payables (2021 - 2025)

Roivant Sciences (ROIV) has disclosed Accounts Payables for 5 consecutive years, with $13.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accounts Payables fell 43.94% year-over-year to $13.3 million, compared with a TTM value of $13.3 million through Dec 2025, down 43.94%, and an annual FY2025 reading of $23.7 million, up 68.87% over the prior year.
  • Accounts Payables was $13.3 million for Q4 2025 at Roivant Sciences, down from $15.1 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $161.3 million in Q2 2022 and bottomed at $11.5 million in Q2 2025.
  • Average Accounts Payables over 5 years is $37.2 million, with a median of $26.4 million recorded in 2024.
  • The sharpest move saw Accounts Payables skyrocketed 974.36% in 2022, then crashed 68.98% in 2023.
  • Year by year, Accounts Payables stood at $24.4 million in 2021, then skyrocketed by 97.06% to $48.0 million in 2022, then decreased by 26.61% to $35.2 million in 2023, then tumbled by 32.69% to $23.7 million in 2024, then crashed by 43.94% to $13.3 million in 2025.
  • Business Quant data shows Accounts Payables for ROIV at $13.3 million in Q4 2025, $15.1 million in Q3 2025, and $11.5 million in Q2 2025.